Olawaiye Alexander B, Rauh-Hain Jose Alejandro, Withiam-Leitch Matthew, Rueda Bo, Goodman Annekathryn, del Carmen Marcela G
Department of Obstetrics, Division of Gynecologic Oncology, Harvard Medical School, Vincent Obstetrics and Gynecology Service, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
Gynecol Oncol. 2008 Sep;110(3):293-8. doi: 10.1016/j.ygyno.2008.05.027. Epub 2008 Jul 21.
To evaluate the usefulness of pre-operative serum CA-125 in the management of women diagnosed with uterine papillary serous carcinoma (UPSC). We hypothesized that elevated pre-operative levels of serum CA-125 correlate with higher disease stage and poorer prognosis.
Patients diagnosed with UPSC and managed in our institution were identified over a period of 10 years, 1995 to 2005. All required information were extracted from their records. The nonparametric test applied for comparison of data included Kruskal Wallis H-test and Man-Whitney U-test. The chi(2) test and Spearman correlation test were used to examine the association of serum CA-125 with different parameters. Receiver operator characteristic curves (ROC) were used to quantify marker performance. Recurrence and survival were analyzed using Kaplan-Meier method. Multivariate analyses were performed with a Cox proportional regression method.
A total of 41 patients met the study criteria. Mean pre-operative serum CA-125 levels were significantly higher in patients with stage IV (1150+/-1297 U/mL), compared with stage III (181+/-232 U/mL; P<0.001), stage II (22+/-9; P<0.001), and stage I (14+/-1; P<0.001). CA-125 correlated strongly with stage (r=0.68, P<0.001). On the ROC, a cut-off of 35 IU/mL provided the best sensitivity and specificity (78% vs. 100% respectively) for extra-uterine disease. Disease free survival (DFS) and overall survival (OS) were longer in patients with CA-125<35 U/mL compared with CA-125>or=35 U/mL [median DFS not reached during study vs. 21.2 months (P=0.009), and median OS not reached during study vs. 25 months, (P=0.0001) respectively]. Multivariate regression model showed CA-125 as the only variable associated with survival (P=0.05).
Pre-operative serum CA-125 levels correlate with stage of disease in patients with UPSC. This may be important for management planning, prognostication and counseling in these women.
评估术前血清CA - 125在子宫浆液性乳头状癌(UPSC)患者管理中的作用。我们假设术前血清CA - 125水平升高与疾病分期较高及预后较差相关。
确定1995年至2005年期间在我们机构诊断并接受治疗的UPSC患者。从他们的记录中提取所有所需信息。用于数据比较的非参数检验包括Kruskal Wallis H检验和Mann - Whitney U检验。使用卡方检验和Spearman相关检验来检查血清CA - 125与不同参数之间的关联。采用受试者操作特征曲线(ROC)来量化标志物性能。使用Kaplan - Meier方法分析复发和生存情况。采用Cox比例回归方法进行多变量分析。
共有41例患者符合研究标准。IV期患者术前血清CA - 125平均水平(1150±1297 U/mL)显著高于III期(181±232 U/mL;P<0.001)、II期(22±9;P<0.001)和I期(14±1;P<0.001)患者。CA - 125与分期密切相关(r = 0.68,P<0.001)。在ROC曲线上,35 IU/mL的临界值对子宫外疾病具有最佳的敏感性和特异性(分别为78%和100%)。与CA - 125≥35 U/mL的患者相比,CA - 125<35 U/mL的患者无病生存期(DFS)和总生存期(OS)更长[研究期间未达到中位DFS,而中位DFS为21.2个月(P = 0.009),研究期间未达到中位OS,而中位OS为25个月,(P = 0.0001)]。多变量回归模型显示CA - 125是与生存相关的唯一变量(P = 0.05)。
术前血清CA - 125水平与UPSC患者的疾病分期相关。这对于这些女性的管理规划、预后评估和咨询可能很重要。